Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q2 2026 results covered quarter ended June 30, 2026.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 absent specific reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales rose to $0.4M from $0.1M, but $1.2M cost of goods sold reflects a $0.7M inventory reserve and unused capacity costs
- V012 Phase 3 interim results showed 91 additional catheter-free days and infection rates of 6 versus 23 per 100 patient years
- Supplemental dialysis BLA planned for the second half of 2026, creating a key regulatory catalyst but no approval yet
- FDA accepted CTEV’s CABG IND, with Phase 2a initiation planned in Q3 2026 and first large-scale manufacturing lot completed
- June offering raised $57.5M; cash, equivalents and restricted cash totaled $80.3M at June 30, supporting commercialization and pipeline development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.